IanTECH Completes Financing co-led by Visionary Ventures and GHIF
Funding for IanTECH’s Next Generation Ophthalmic Device Supports Goal to Alleviate Cataract-induced Blindness in 25 Million.
Funding for IanTECH’s Next Generation Ophthalmic Device Supports Goal to Alleviate Cataract-induced Blindness in 25 Million.
TearClear closes series A financing and introduces leadership team of accomplished ophthalmology veterans with the proceeds going to advance the development of the Company’s delivery system for preservative-free ophthalmic drugs.
The Economic Impact of the Ophthalmic Goods Manufacturing Industry on the Southern California Economy.